ADVENTRX to Present at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
March 23 2006 - 1:00PM
PR Newswire (US)
SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that Evan M.
Levine, president and CEO, will deliver a corporate overview at the
CIBC World Markets Annual Biotechnology & Specialty
Pharmaceuticals Conference. Mr. Levine's presentation is scheduled
for Wednesday, April 5 at 8:30 AM in Room 3.04. The conference will
take place at the Millennium Broadway Hotel in New York City, April
4-5, 2006. A live webcast of Mr. Levine's presentation will be
available via the Internet by visiting the "Investors" section of
the Company's Web site at
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-calendar.
The conference will feature informative presentations and panels
from over 80 public and private healthcare companies, clinical
investigators and research scientists. For more information on the
conference, visit
http://conferences.cibcwm.com/biotech06/index.html. About ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on introducing new anticancer and
antiviral treatments that surpass the performance and safety of
existing drugs, by addressing significant problems such as drug
metabolism, toxicity, bioavailability and resistance. More
information can be found on the Company's Web site at
http://www.adventrx.com/. Forward-Looking Statement This press
release contains forward-looking statements, within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995, regarding ADVENTRX. Such statements are made
based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the FDA and other regulatory agencies. For a
discussion of such risks and uncertainties, which could cause
actual results to differ from those contained in the
forward-looking statements regarding ADVENTRX, see the section
titled "Risk Factors" in ADVENTRX's last annual report on Form
10-K, as well as other reports that ADVENTRX files from time to
time with the Securities and Exchange Commission. All
forward-looking statements regarding ADVENTRX are qualified in
their entirety by this cautionary statement. ADVENTRX undertakes no
obligation to release publicly any revisions, which may be made to
reflect events or circumstances after the date hereof. DATASOURCE:
ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX
Pharmaceuticals, +1-858-552-0866 Web site:
http://conferences.cibcwm.com/biotech06/index.html Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024